

EuroEyes

EuroEyes International Eye Clinic Limited

德視佳國際眼科有限公司

(Stock Code: 1846)

EuroEyes Announces Positive Profit Alert Expects to Achieve A Turnaround in the 2020 Annual Results

[22 February 2021, Hong Kong] **EuroEyes International Eye Clinic Limited** (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, stock code: 1846), is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and 25 years of experience with individualised customer-care. The Group is principally engaged in the provision of vision correction services in Germany, Denmark and the People’s Republic of China (“the PRC”). The Company is pleased today to announce its Positive Profit Alert for the year ended 31 December 2020 (the “Year”).

Despite COVID-19 pandemic in Denmark, Germany and the PRC that caused partial lockdown of the Group’s facilities, EuroEyes achieved revenue growth and expects to record a profit attributable to owners of the Company between HK\$63 million and HK\$66 million for the Year (FY2019: a loss of approximately HK\$3.4 million attributable to the owners of the Company), achieving turnaround in the results.

The turnaround in the Year is primarily attributable to the increase in the total number of eye surgeries performed by the Group. Besides, the provision of one-off non-deductible listing expenses of approximately HK\$42.2 million that was recognised in 2019 also contributed to the significant improvement.

Dr. Jørn Slot Jørgensen, the Founder, Chairman and CEO of EuroEyes, said, “We are glad that the Group is expected to record a turnaround from loss to profit over the turbulent year. Although the COVID-19 pandemic constituted an unprecedented shock to the global economy last year, I am proud that we have made timely internal optimizations, took all measures to ensure our staff’s safety and none of our staff in Germany, Denmark and the PRC has been diagnosed with COVID-19. We worked tirelessly to provide patients with high-quality services, and continue to pursue our goal for ‘Nie wieder Brille!’ (No More Glasses), so as to achieve an excellent results performance. We will regularly and closely monitor the development of the COVID-19 pandemic and assess its impact on the operations and financial performance of the Group, continue to leverage our strengths as the market leader in Germany, further expand our market share and strive to create the greatest investment return for investors. Thank you again for believing in us and your support.”